Conclusions

In the INBUILD trial in subjects with progressive fibrosing ILDs, nintedanib had a consistent effect on reducing the rate of decline in FVC in subjects who did and did not use DMARDs and/or glucocorticoids at baseline.
The adverse event profile of nintedanib was consistent between subgroups by use of DMARDs and/or glucocorticoids at baseline.